AAPG · Ascentage Pharma Group International
Market Cap
$1.61B
Shares
93.39M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Diluted EPS
-$0.18
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2024 |
|---|---|
| USD/shares | -$0.18 |
| USD/shares | -$0.18 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2023: $32.7M in buybacks.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (CNY)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Chinese Mainland | 574,120,000 | 302,235,000 | 221,984,000 | 209,707,000 |
| Switzerland | — | 678,415,000 | — | — |
| United States | — | — | — | 4,000 |
By Product & Service (CNY)
| Component | FY2024 |
|---|---|
| Intellectuall Property | 678,415,000 |